tenayatherapeutics.com (TNYA) - Long-Term Liabilities to Capital

The Tenaya Therapeutics (TNYA) price chart on the GURU.Markets platform reflects the asset's dynamics, where the indicator stands at 0.02. The company's revenues are based on bringing gene therapies for heart failure and cardiomyopathies to market. The absence of in-house manufacturing plants, achieved by outsourcing production to contractors, ensures team mobility. Meanwhile, an intensive R&D cycle enables the accelerated development of breakthrough treatments for cardiac pathologies.

This ratio determines the extent to which the financing structure depends on long-term borrowings relative to equity, measuring financial leverage and insolvency risk. For Tenaya Therapeutics (TNYA), which currently lacks pricing power in gene therapy, an analysis of long-term debt-to-equity confirms the company's ability to fund R&D without a critical debt burden until the monetization of its unique treatments.